Bone Biologics Corp
For the period ended Sep 30, 2026. Filed Oct 26, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 26, 2026
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
| Nine months Ended September 30, 2026 · Nine months Ended September 30, 2025 | ||||
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net loss | $(2,157,341) | $(2,424,348) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation-fair value of vested stock options | 35,183 | 210,684 | ||
| Change in fair value of warrant liability | (505) | (3,469) | ||
| Changes in operating assets and liabilities: | ||||
| Advances on research and development contract services | - | 37,773 | ||
| Prepaid insurance | 169,201 | 196,750 | ||
| Interest receivable | 918 | - | ||
| Accounts payable and accrued expenses | 97,547 | 6,222 | ||
| Net cash used in operating activities | (1,854,997) | (1,976,388) | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of common shares from ATM, net of costs | 20,180 | 347,549 | ||
| Proceeds from sale of common stock, pre-funded warrants and warrants in public offering, net of offering costs | - | 4,352,792 | ||
| Proceeds from sale of pre-funded warrants and warrants in private placement, net of offering costs | 2,639,667 | - | ||
| Exercise of pre-funded warrants | 1,579 | - | ||
| Deferred offering costs | (52,666) | - | ||
| Net cash provided by financing activities | 2,608,760 | 4,700,341 | ||
| Net increase in cash | 753,763 | 2,723,953 | ||
| Cash, beginning of period | 5,334,322 | 3,325,131 | ||
| Cash, end of period | $6,088,085 | $6,049,084 | ||
| Supplemental information | ||||
| Income taxes paid | $ | - | $ | - |
| Noncash investing and financing activities | ||||
| Options issued to settle accrued bonus | $34,854 | $46,183 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.